FSGS Clinical Trials

7 recruiting

Frequently Asked Questions

Common questions about FSGS clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 1

A Study to Evaluate the Safety, Tolerability and PK of SK-09

FSGSMCD
Consun Pharmaceutical Group72 enrolled1 locationNCT07267026
Recruiting
Not Applicable

NEPTUNE Match Study

Nephrotic Syndrome in ChildrenAlport SyndromeFocal Segmental Glomerulosclerosis+6 more
University of Michigan375 enrolled16 locationsNCT04571658
Recruiting
Phase 3

A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB

FSGS
Dimerix Bioscience Pty Ltd286 enrolled220 locationsNCT05183646
Recruiting
Phase 2

Atacicept in Multiple Glomerular Diseases

IgANNephrotic SyndromeFSGS+2 more
Vera Therapeutics, Inc.200 enrolled1 locationNCT06983028
Recruiting

Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.

EdemaNephrotic Syndrome in ChildrenMembranous Nephropathy+10 more
University of Michigan150 enrolled1 locationNCT05505500
Recruiting
Phase 1

A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of VIS171 in Participants With Autoimmune Disease(s)

Systemic Lupus Erythematosus (SLE)Alopecia Areata (AA)Immune-mediated Focal Segmental Glomerulosclerosis (FSGS)
Otsuka Pharmaceutical Development & Commercialization, Inc.30 enrolled6 locationsNCT06799520
Recruiting

Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease

Focal Segmental GlomerulosclerosisMinimal Change DiseaseFSGS+1 more
University of Michigan300 enrolled1 locationNCT05650619
Recruiting
Phase 1Phase 2

Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor

CystinosisCKD Stage 4FSGS+2 more
Alice Bertaina12 enrolled1 locationNCT05508009
Recruiting
Phase 3

A Pivotal Phase 3 Study of the Efficacy and Safety of DMX-200 in Patients With focal segmental glomerulosclerosis (FSGS) Who Are Receiving an angiotensin II receptor blocker (ARB)

Focal segmental glomerulosclerosis (FSGS)
Dimerix Bioscience Pty Ltd286 enrolled20 locationsACTRN12622000066785